Nanoplatform-mediated PRMT3 inhibition synergizes cuproptosis and radiotherapy to remodel the NSCLC immune microenvironment

Key Points

• Inhibition of PRMT3 enhances cuproptosis in non-small cell lung cancer (NSCLC), leading to significant immune remodeling.
• The combination approach, utilizing nanoplatforms and radiotherapy, shows improved efficacy in targeting NSCLC tumor environments.
• Analysis incorporated various molecular pathways and their interactions within the immune microenvironment.
• This work highlights the potential for innovative combinatory therapies, especially for lung cancer treatment.